{"title":"Strategies to extend plasma half-lives of recombinant antibodies.","authors":"Roland E Kontermann","doi":"10.2165/00063030-200923020-00003","DOIUrl":null,"url":null,"abstract":"<p><p>Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":"23 2","pages":"93-109"},"PeriodicalIF":6.9000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00063030-200923020-00003","citationCount":"200","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioDrugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2165/00063030-200923020-00003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 200
Abstract
Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.
期刊介绍:
An essential resource for R&D professionals and clinicians with an interest in biologic therapies.
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.
BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.